CEPTON Strategies | A Vintura company

📰 Dans une tribune récente pour le journal Le Monde, Thomas Rapp, professeur d’économie et senior advisor chez CEPTON Strategies | A Vintura company, met en avant le besoin d’améliorer l’efficience du système de santé français, en réduisant le gaspillage des soins, en faisant évoluer le système de tarification, et en déployant des accords de performance pour améliorer l’accès aux innovations de santé. 💡 Pour en savoir plus et découvrir les idées proposées, cliquez ici:

🚀 Year after year, CEPTON Strategies | A Vintura company continues to achieve remarkable growth, driven by the trust of our valued clients and the exceptional performance of our talented team. We take great pride in seeing our people grow and develop at every level, making a lasting impact on our success and the future of healthcare strategy.   👏 We are thrilled to announce the recent promotions of Juliette Mercury and Allan Beke, Ph.D. to Principal, Bichai YIN 殷璧钗 to Manager, and Diana Daher, Hermine Paulhac, and Jonathan Deloule to Senior Consultant. 🌟 They have shown exceptional dedication, leadership, and expertise in driving our mission forward. Their contributions have been instrumental in delivering value and innovation to our clients, and we’re excited to see the incredible impact they will continue to make in their new roles. 🚀Congratulations again to all! We look forward to seeing your continued success and the positive influence! #strategyconsulting #careerdevelopment #leadershipgrowth #ceptonjourney #healthcarestrategy

👏🏻 Congratulations to Acteon Group and DENTRESSANGLE (majority stakeholder of Acteon) on their strategic investment in Inibsa (alongside with Septodont as controlling shareholder)! 🦷Inibsa, with 75 years of experience, is a global pharmaceutical group specializing in the development and manufacturing of high quality products for dental practitioners in 60+ countries. This investment will help Inibsa accelerate growth, while Acteon strengthens its manufacturing position in dental pharmaceuticals across Europe and Asia. 🚀 At CEPTON Strategies | A Vintura company, we’re proud to have supported Dentressangle through Commercial Due Diligence for this transaction. Our team’s analysis included a detailed review of market trends, competitive landscape, and strategic fit, validating Inibsa’s growth potential and long-term sustainability. 🔗 Learn more about this exciting deal here: https://lnkd.in/gVtcj7_J We look forward to seeing the impact this strategic partnership will bring to the dental healthcare industry! 🙏 Thanks to Dentressangle team (Thierry Coloigner, Charles Wacheux, Alexis Fontaine, Arthur Baral) and Acteon team (Markus Boehringer, Kristel Rolland, Pierre Verdet, Jean-Charles Le Corre) for your trust and thanks to Cepton team (Matthias BUCHER, Camille Bertin, Lucas Pruvot, Binghao JIA, Diana Daher, Jérémie Wisniewski) leading this Due Diligence! #CeptonStrategies #DealAdvisory #PrivateEquity #CommercialDueDiligence #Dentressangle #Acteon #Septodont #Inibsa #DentalIndustry #Investment #StrategicPartnership

👏🏻 Congratulations to Bruker on their strategic minority investment in Novalix, a specialized drug discovery CRO focused on biostructural and biophysical sciences with preclinical capacity (including in vivo models). NovAliX is renowned for its innovative approaches within the drug discovery landscape, emphasizing cutting-edge biophysical and structural analysis.  This strategic investment will accelerate NovAliX’s growth and enhance its positioning as a leader in biostructural drug discovery, aligning with evolving industry demands and providing significant value to its clients. 🚀 At Cepton Strategies, we’re proud to have played a key role in this deal through Vendor Due Diligence. Our work included a deep dive into market trends and emerging technologies, helping to validate NovAliX’s competitive edge. We also assessed the company’s business sustainability, ensuring that their revenue streams and growth strategies align with the evolving demands of the drug discovery landscape. Together, we are excited about the future growth and impact this partnership will bring to the field of drug discovery! 🔗 Learn more about this exciting deal here: https://lnkd.in/dWfV2rZV 🙏 Thanks to NovAlix team (Stephan Jenn, Denis Z., Christophe D.) and Augustin Viellard from Rothschild & Co for your trust and thanks to Cepton team ( Matthias BUCHER, Camille Bertin, Allan Beke, Ph.D., Hermine Paulhac, Jean-Baptiste Boyssou) leading this Vendor Due Diligence!

📣 Cepton/Vintura is excited to join IPEMPARIS 2024 on September 10-11 in Paris, the greatest event in European private capital organized by IPEM🤝 Come and meet 2 of our Partners, Matthias BUCHER and Camille Bertin during the event! #IPEM2024 #privateequity #strategyconsulting #duediligence #healthcare

🌟 Exciting News! 🌟 We are thrilled to announce that CEPTON Strategies has been recognized as a leading strategic consulting firm in healthcare by Décideurs Magazine for the 7th year in a row! 🏆 Specializing in pharma, biotech, medtech, and health sectors, we advise corporate players and investment funds on corporate strategy, organization, growth, performance, and transaction support. Our merger with Vintura has expanded our reach with offices in Paris, Amsterdam, London, and Munich. This, combined with our strong sector expertise, attracts major clients. Our dedicated teams respond swiftly and effectively to our clients' needs, enhancing our presence internationally in all healthcare and life sciences sectors. Thank you to our dedicated team and valued clients for your trust and partnership. Together, we are making a difference! 💼💡💊 Check out the full ranking here: https://lnkd.in/dt_9EQRH #Healthcare #StrategyConsulting #CEPTONStrategies #Innovation #Excellence #HealthcareConsulting #Pharma #Biotech #Medtech #PrivateEquity

🎺 Promising insights of our Partner Marc-Olivier Bévierre from the #BIO convention in San Diego for #Biotechfundraising ! What are your thoughts? Come comment and vote! 📢

👏🏻 Congratulations to IK Partners's new investment in BIOBank S.A., through the acquisition of a majority stake from Verto, Capital Croissance and the management team, who will all be reinvesting.   Headquartered in France, BIOBank is now a leading European human tissue bank of bone allografts for orthopaedic, spinal, dental and CMF surgeries, across the full value chain from collecting bone tissue to transformation and distribution. BIOBank holds more than 50% market share in France and addresses 8 additional international markets with significant growth.   With IK Partners and the existing sponsors, the company wishes to pursue further growth in France through distribution network reinforcement and new products launch and to accelerate organic international expansion and inorganic growth through selective buy-and-build strategy.   🚀 At Cepton, we take pride in our significant contribution to the Vendor Due Diligence process, which played a pivotal role in facilitating this remarkable investment.   🙏 Thanks to BIOBank S.A. team (Alexandre Tepas, Raphaël Bardonnet, Patrick Joucla, Audrey Zazzera, Jérôme Vacheron, Thierry Scandola, Samantha Audibert, Gregoire Edorh, PhD), Verto team (Thomas Fort, Antoine Dary), Capital Croissance team(Julie Masson) and Edmond de Rothschild team (Arnaud Petit, Anastasia Saldi Lourties, Emeric Masurel) for your trust and thanks to Cepton team Maxime Bourdon, Allan Beke, Ph.D., Robinson Tillet, Binghao JIA, Alan Kotun, Arthur Raymond leading this Vendor Due Diligence!   #strategyconsulting  #privateequity  #vendorduediligence  #lifesciences

L'équipe Cepton Strategies participe à la table ronde des Cercles Décideurs Santé sur le thème 💡 "Quelles tendances d'outsourcing face aux innovations disponibles sur le marché ?”   Les stratégies Make or Buy sont au coeur de l'évolution de l'écoystème pharma et biotech et créent des changement organisationnels profonds ainsi que des opporunités d'investissements attractives - autant de problématiques clés pour les dirigeants de ce secteur.   Retrouvez-nous ce jeudi à l'Hôtel Crillon !   🗓 Jeudi 04 avril 🕣 8h30 - 11h00 📍 Hôtel Crillon (75008)   #pharma #biotech #makeorbuy #technology #conference

👏🏻 Congratulations to Eurazeo on their recent investment in KINVENT, a leader in advanced biomechanical solutions designed to enhance physical therapy and sports rehabilitation practices. With Eurazeo's €16M investment through Nov Santé Actions, Kinvent is embarking on a new phase of acceleration to strengthen its positions in key markets and penetrate new ones, including the American market. Congratulations Athanase (Athan) Kollias and your team!    🚀 At Cepton, we are proud to have contributed to the commercial due diligence process that helped enable this exciting investment. Thanks Eurazeo team for your trust Arnaud Vincent, Samantha Schwartz, Simon Mauclair, and thanks to Cepton team leading this Commercial Due Diligence Matthias BUCHER, Florian Bertelli, Robinson Tillet, Salma Lemhadri!   #strategyconsulting  #commercialduediligence  #lifesciences #medicaldevices